Rare diseases
Investigational molecules
Locations
A plain-language summary of the goals, design and what participants do
This study focuses on Fetal Growth Restriction, a condition where an unborn baby is smaller than expected or growing at an abnormal rate during pregnancy. The research examines the effectiveness of enoxaparin sodium, a medication given as an injection under the skin, in treating early stages of this condition. This medication belongs to a group of drugs called low molecular weight heparins, which are commonly used to prevent blood clots.
The purpose of this study is to determine if this treatment can help extend the time babies with growth restriction can stay in the womb before delivery is necessary. The medication being tested is Enoxaparin Rovi, which comes in pre-filled syringes containing 4,000 international units (40 mg) of the active substance. Participants will receive daily injections under the skin for up to 24 weeks during their pregnancy.
During the study, various aspects of both the mother's and baby's health will be monitored through regular check-ups. These include checking the blood flow to the baby and through the placenta, tracking the baby's growth, and monitoring the mother's health throughout pregnancy. The study will also look at important outcomes such as the baby's birth weight, overall health at birth, and any complications that may occur during pregnancy or delivery.
The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.
7 criteria
14 criteria
Tell us about your condition – we search every trial in Europe and connect you with the right site.
We usually reply within a few days
Where you can join this trial
Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.
RecruitingJoining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.
is a blood-thinning medication (low molecular weight heparin) that helps prevent blood clots. In this trial, it is being studied for its potential to help improve fetal growth during pregnancy. The medication works by making the blood less likely to form clots, which may help improve blood flow to the developing baby through the placenta.
(low molecular weight) belongs to a class of medications called anticoagulants. It is commonly used to prevent and treat blood clots. In pregnancy-related research, it is being investigated for its potential benefits in cases where the baby is not growing as expected in the womb. The medication is typically given as an injection under the skin.
Other trials in this disease – keep exploring while you decide
FranceFrance
Spainsourced from the EU Clinical Trials Register and site verification
Want to learn more about this trial or check if you can participate?
Tell us about your condition – we search every trial in Europe and connect you with the right site.
